BioXcel Therapeutics (NASDAQ:BTAI) Shares Down 8.6% Following Insider Selling
BioXcel Therapeutics (NASDAQ:BTAI) Shares Down 8.6% Following Insider Selling
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating)'s share price traded down 8.6% during trading on Wednesday after an insider sold shares in the company. The company traded as low as $29.82 and last traded at $29.93. 209,236 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 356,040 shares. The stock had previously closed at $32.73.
在一名内部人士抛售该公司股票后,BioXcel Treateutics,Inc.(纳斯达克代码:BTAI-GET Rating)的股价周三下跌8.6%。该公司股价最低跌至29.82美元,最新报29.93美元。209,236股午盘易手,较356,040股的平均成交量下跌41%。该股此前收盘报32.73美元。
Specifically, insider Frank Yocca sold 50,000 shares of BioXcel Therapeutics stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $30.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the insider now owns 8,397 shares in the company, valued at approximately $251,910. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Krishnan Nandabalan sold 27,450 shares of the business's stock in a transaction that occurred on Thursday, November 10th. The shares were sold at an average price of $15.00, for a total transaction of $411,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Frank Yocca sold 50,000 shares of the business's stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $30.00, for a total transaction of $1,500,000.00. Following the transaction, the insider now owns 8,397 shares of the company's stock, valued at approximately $251,910. The disclosure for this sale can be found here. Insiders sold a total of 133,339 shares of company stock worth $3,073,310 in the last quarter. 37.00% of the stock is owned by company insiders.
具体地说,内部人士Frank Yocca在1月20日星期五的一笔交易中出售了50,000股BioXcel治疗公司的股票。这些股票以30.00美元的平均价格出售,总成交额为1500,000.00美元。出售完成后,这位内部人士现在拥有该公司8,397股,价值约251,910美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过这个环节。在相关新闻中,董事Krishnan Nandabalan在11月10日星期四的一笔交易中出售了27,450股该业务的股票。这些股票以15.00美元的平均价格出售,总成交金额为411,750.00美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过这个环节。此外,内部人士弗兰克·约卡在1月20日星期五的一次交易中出售了50,000股该公司的股票。这些股票以30.00美元的平均价格出售,总成交额为1500,000.00美元。交易完成后,这位内部人士现在拥有该公司8,397股股票,价值约251,910美元。关于这次销售的披露可以找到这里。上个季度,内部人士总共出售了133,339股公司股票,价值3,073,310美元。37.00%的股份由公司内部人士持有。
Analyst Upgrades and Downgrades
分析师升级和下调评级
A number of research analysts recently issued reports on the stock. HC Wainwright decreased their price objective on shares of BioXcel Therapeutics from $85.00 to $73.00 and set a "buy" rating for the company in a report on Tuesday, January 3rd. Mizuho lifted their price target on shares of BioXcel Therapeutics from $18.00 to $24.00 in a research note on Thursday, December 15th. Canaccord Genuity Group lifted their price target on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the company a "buy" rating in a research note on Friday, November 11th. Guggenheim cut their price target on shares of BioXcel Therapeutics from $28.00 to $25.00 and set a "buy" rating on the stock in a research note on Friday, November 11th. Finally, The Goldman Sachs Group raised shares of BioXcel Therapeutics from a "sell" rating to a "neutral" rating and set a $16.00 price target on the stock in a research note on Thursday, December 1st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $51.78.
一些研究分析师最近发布了关于该股的报告。HC Wainwright将BioXcel治疗公司的股票目标价从85.00美元下调至73.00美元,并在1月3日星期二的一份报告中为该公司设定了“买入”评级。瑞穗在12月15日星期四的一份研究报告中将BioXcel治疗公司的股票目标价从18.00美元上调至24.00美元。11月11日,星期五,Canaccel Genuity Group将BioXcel治疗公司的股票目标价从75.00美元上调至76.00美元,并在一份研究报告中给予该公司“买入”评级。11月11日,古根海姆将BioXcel治疗公司的股票目标价从28.00美元下调至25.00美元,并在一份研究报告中对该股设定了“买入”评级。最后,高盛在12月1日(星期四)的一份研究报告中将BioXcel治疗公司的股票评级从“卖出”上调至“中性”,并为该股设定了16.00美元的目标价。一位研究分析师对该股的评级为持有,七位分析师对该公司的评级为买入。根据MarketBeat.com的数据,该股目前的平均评级为“中等买入”,平均目标价为51.78美元.
BioXcel Therapeutics Stock Performance
BioXcel治疗公司股票表现
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.15). The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.05 million. As a group, equities analysts predict that BioXcel Therapeutics, Inc. will post -5.37 EPS for the current year.
BioXcel治疗公司(纳斯达克代码:BTAI-GET Rating)上一次公布季度收益数据是在11月10日星期四。该公司公布了该季度每股收益(1.49美元),低于分析师普遍预期的(1.34美元)和(0.15美元)。该公司本季度营收为14万美元,而分析师预期为305万美元。作为一个整体,股票分析师预测BioXcel治疗公司本年度将公布每股收益5.37美元。
Institutional Trading of BioXcel Therapeutics
BioXcel治疗公司的制度性交易
A number of institutional investors have recently made changes to their positions in BTAI. Point72 Hong Kong Ltd bought a new stake in shares of BioXcel Therapeutics in the second quarter worth $50,000. Quantbot Technologies LP acquired a new position in BioXcel Therapeutics during the third quarter worth $57,000. Amalgamated Bank acquired a new position in BioXcel Therapeutics during the first quarter worth $59,000. Game Plan Financial Advisors LLC acquired a new position in BioXcel Therapeutics during the second quarter worth $142,000. Finally, Virtus ETF Advisers LLC increased its holdings in BioXcel Therapeutics by 46.3% during the second quarter. Virtus ETF Advisers LLC now owns 11,284 shares of the company's stock worth $149,000 after buying an additional 3,571 shares during the last quarter. Institutional investors own 42.35% of the company's stock.
一些机构投资者最近改变了他们在BTAI的头寸。Point72 Hong Kong Ltd在第二季度购买了BioXcel治疗公司价值5万美元的新股。Quantbot Technologies LP在第三季度收购了BioXcel治疗公司的一个新头寸,价值5.7万美元。合并银行在第一季度收购了BioXcel治疗公司的一个新头寸,价值59,000美元。游戏计划财务顾问公司在第二季度收购了BioXcel治疗公司的一个新头寸,价值14.2万美元。最后,Virtus ETF Advisers LLC在第二季度将其在BioXcel治疗公司的持股增加了46.3%。Virtus ETF Advisers LLC现在拥有11,284股该公司股票,价值149,000美元,上个季度又购买了3,571股。机构投资者持有该公司42.35%的股票。
About BioXcel Therapeutics
关于BioXcel治疗公司
(Get Rating)
(获取评级)
BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
BioXcel治疗公司是一家商业阶段的生物制药公司,利用人工智能方法开发神经科学和免疫肿瘤学的变革性药物。该公司的药物再创新方法利用现有的批准药物和/或临床验证的候选产品,以及大数据和专有机器学习算法来识别新的治疗指数。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on BioXcel Therapeutics (BTAI)
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- 免费获取StockNews.com关于BioXcel治疗(BTAI)的研究报告
- 两大股利大王:强生还是雅培?
- 网络安全类股已经见底了吗?
- 联合太平洋,诺福克南方进入购买区
- 柔顺治疗公司的差距增加了34%:未来还会有更多的好处吗?
- 2023年初裁员将如何影响这5只生物科技股?
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受BioXcel治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioXcel治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。